Thrombocytosis

Chapter

Abstract

An elevated platelet count, typically referred to as thrombocytosis or thrombocythemia, is usually defined as an increase in platelet counts above 500,000/μl from a routine complete blood count measurement. However, some neoplastic hematologic disorders use a cutoff point of ≥450,000/μl to define thrombocytosis, as is the case with a provisional subtype of myelodysplastic/myeloproliferative overlap neoplasm (MDS/MPN) called refractory anemia with ring sideroblasts (RARS) associated with marked thrombocytosis (RARS-T) and essential thrombocythemia (ET) (Swerdlow et al., WHO classification of tumours of haematopoietic and lymphoid tissues, 2008). Occasionally platelet counts can increase to >1,000,000/μl and are referred to as extreme thrombocytosis. The etiologies of thrombocytosis are generally divided into primary or secondary causes. Primary causes are usually related to an underlying clonal hematologic cancer that causes autonomous proliferation of megakaryocytes. The most common diseases causing autonomous thrombocytosis are myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MDS/MPN overlap neoplasms. Secondary causes are typically reactive and account for the vast majority of all thrombocytosis cases encountered in clinical practice. Secondary thrombocytosis is primarily cytokine mediated and includes etiologies such as infection, connective tissue diseases, postsurgical, post-splenectomy, acute blood loss, iron-deficiency anemia, other cancers, and medications. Clinically, thrombocytosis, regardless of etiology, can also be associated with vasomotor (lightheadedness, headaches, atypical chest pain, erythromelalgia and visual disturbances, peripheral dysesthesias), thrombotic, and bleeding complications. However, the risk of bleeding, thrombotic complications, and vasomotor symptoms are usually seen with primary causes of thrombocytosis and only rarely in secondary thrombocytosis. Spurious causes of thrombocytosis can include mixed cryoglobulinemia and cytoplasmic fragments in patients with leukemia/lymphoma. We present here a series of clinical vignettes describing unique patient cases of thrombocytosis associated with various etiologies and their management.

Keywords

Leukemia Heparin Anemia Thrombocytopenia Thrombin 

References

  1. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121:943–8.PubMedCentralPubMedCrossRefGoogle Scholar
  2. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73:405–10.PubMedCrossRefGoogle Scholar
  3. Avraham H, Banu N, Scadden DT, Abraham J, Groopman JE. Modulation of megakaryocytopoiesis by human basic fibroblast growth factor. Blood. 1994;83:2126–32.PubMedGoogle Scholar
  4. Balatzenko G, Guenova M, Zechev J, Toshkov S. Acute megakaryoblastic leukaemia with extreme thrombocytosis and p190(bcr/abl)rearrangement. Ann Hematol. 2004;83:381–5.PubMedCrossRefGoogle Scholar
  5. Ballen KK, et al. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012;18:1446–54.PubMedCentralPubMedCrossRefGoogle Scholar
  6. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.PubMedCrossRefGoogle Scholar
  7. Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev. 2012;26:205–11.PubMedCrossRefGoogle Scholar
  8. Buss DH, Cashell AW, O’Connor ML, Richards 2nd F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247–53.PubMedCrossRefGoogle Scholar
  9. Carbone PP, Bono V, Frei 3rd E, Brindley CO. Clinical studies with vincristine. Blood. 1963;21:640–7.PubMedGoogle Scholar
  10. Casella I, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101:1316–23.PubMedCrossRefGoogle Scholar
  11. Cheng EC, et al. Role for MKL1 in megakaryocytic maturation. Blood. 2009;113:2826–34.PubMedCrossRefGoogle Scholar
  12. Cogswell ME, Looker AC, Pfeiffer CM, Cook JD, Lacher DA, Beard JL, Lynch SR, Grummer-Strawn LM. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003–2006. Am J Clin Nutr. 2009;89:1334–42.PubMedCrossRefGoogle Scholar
  13. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119–25.PubMedCrossRefGoogle Scholar
  14. Cramer EM, Norol F, Guichard J, Breton-Gorius J, Vainchenker W, Masse JM, Debili N. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood. 1997;89:2336–46.PubMedGoogle Scholar
  15. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol. 2005;129:165–77.PubMedCrossRefGoogle Scholar
  16. Dastugue N, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood. 2002;100:618–26.PubMedCrossRefGoogle Scholar
  17. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–63.PubMedCrossRefGoogle Scholar
  18. Ebert BL, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451:335–9.PubMedCentralPubMedCrossRefGoogle Scholar
  19. Ehrenfeld M, Penchas S, Eliakim M. Thrombocytosis in rheumatoid arthritis. Recurrent arterial thromboembolism and death. Ann Rheum Dis. 1977;36:579–81.PubMedCrossRefGoogle Scholar
  20. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995;98:551–8.PubMedCrossRefGoogle Scholar
  21. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRefGoogle Scholar
  22. Folman CC, Ooms M, Kuenen BB, de Jong SM, Vet RJ, de Haas M, von dem Borne AE. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol. 2001;114:126–33.PubMedCrossRefGoogle Scholar
  23. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, Tefferi A. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270–6.PubMedCrossRefGoogle Scholar
  24. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol. 1993;83:433–41.PubMedCrossRefGoogle Scholar
  25. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford). 2006;45 Suppl 3:iii3–4.Google Scholar
  26. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372–82.PubMedCrossRefGoogle Scholar
  27. Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMedGoogle Scholar
  28. Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.PubMedCrossRefGoogle Scholar
  29. Greer JP, Foerster J, Lukens JN. Wintrobe’s clinical hematology. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 1981. p. 1128–34.Google Scholar
  30. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245:295–300.PubMedCrossRefGoogle Scholar
  31. Gu TL, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 2007;110:323–33.PubMedCrossRefGoogle Scholar
  32. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998;70:210–4.PubMedCrossRefGoogle Scholar
  33. Harris RA, Penington DG. The effects of low-dose vincristine on megakaryocyte colony-forming cells and megakaryocyte ploidy. Br J Haematol. 1984;57:37–48.PubMedCrossRefGoogle Scholar
  34. Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.PubMedCrossRefGoogle Scholar
  35. Hirsh J, McBride JA, Dacie JV. Thrombo-embolism and increased platelet adhesiveness in post-splenectomy thrombocytosis. Australas Ann Med. 1966;15:122–8.PubMedGoogle Scholar
  36. Hoffman R, et al. Hematology: basic principles and practice. 4th ed. New York: Churchill Livingstone; 2005. Chapter 71.Google Scholar
  37. Hou M, Andersson PO, Stockelberg D, Mellqvist UH, Ridell B, Wadenvik H. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol. 1998;101:420–4.PubMedCrossRefGoogle Scholar
  38. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.PubMedCrossRefGoogle Scholar
  39. Ikeda Y, Miyakawa Y. Development of thrombopoietin receptor agonists for clinical use. J Thromb Haemost. 2009;7 Suppl 1:239–44.PubMedCrossRefGoogle Scholar
  40. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012;87:1037–45.PubMedCrossRefGoogle Scholar
  41. Jackson CW, Edwards CC. Evidence that stimulation of megakaryocytopoiesis by low dose vincristine results from an effect on platelets. Br J Haematol. 1977;36:97–105.PubMedCrossRefGoogle Scholar
  42. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:171–3.PubMedCrossRefGoogle Scholar
  43. Kantarjian H, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.PubMedCrossRefGoogle Scholar
  44. Kaser A, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720–5.PubMedCrossRefGoogle Scholar
  45. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234–8.PubMedCentralPubMedCrossRefGoogle Scholar
  46. Khan PN, Nair RJ, Olivares J, Tingle LE, Li Z. Postsplenectomy reactive thrombocytosis. Proc (Bayl Univ Med Cent). 2009;22:9–12.Google Scholar
  47. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J. Med. 2013;369(25):2379–90.Google Scholar
  48. Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.PubMedCrossRefGoogle Scholar
  49. Liautard C, Nunes AM, Vial T, Chatillon F, Guy C, Ollagnier M, Descotes J. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother. 2002;36:1351–4.PubMedCrossRefGoogle Scholar
  50. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer. 1994;74:90–2.PubMedCrossRefGoogle Scholar
  51. Losada R, Espinosa E, Hernandez C, Dorticos E, Hernandez P. Thrombocytosis in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment. Br J Haematol. 1996;95:704–5.PubMedCrossRefGoogle Scholar
  52. Malcovati L, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.PubMedCrossRefGoogle Scholar
  53. Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.PubMedCrossRefGoogle Scholar
  54. Min X, Na Z, Yanan L, Chunrui L. De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome. J Hematol Oncol. 2011;4:45.PubMedCentralPubMedCrossRefGoogle Scholar
  55. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663–8.PubMedCentralPubMedCrossRefGoogle Scholar
  56. Moloney WC. Radiogenic leukemia revisited. Blood. 1987;70:905–8.PubMedGoogle Scholar
  57. Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916–8.PubMedGoogle Scholar
  58. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J. Med. 2013;369(25):2391–405.Google Scholar
  59. Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA. Transcription factor GATA-1 in megakaryocyte development. Stem Cells. 1998;16 Suppl 2:79–83.PubMedGoogle Scholar
  60. Papa A, et al. Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. Hepatogastroenterology. 2003;50:132–5.PubMedGoogle Scholar
  61. Passamonti F, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13–8.PubMedGoogle Scholar
  62. Peterson BA, Levine EG. Uncommon subtypes of acute nonlymphocytic leukemia: clinical features and management of FAB M5, M6 and M7. Semin Oncol. 1987;14:425–34.PubMedGoogle Scholar
  63. Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26:563–71.PubMedCrossRefGoogle Scholar
  64. Rizzieri DA, Wong WM, Gockerman JP. Thrombocytosis associated with low-molecular-weight heparin. Ann Intern Med. 1996;125:157.PubMedCrossRefGoogle Scholar
  65. Robertson JH, McCarthy GM. Periwinkle alkaloids and the platelet-count. Lancet. 1969;2:353–5.PubMedCrossRefGoogle Scholar
  66. Roumier C, Daudignon A, Soenen V, Dupriez B, Wetterwald M, Lai JL, Cosson A, Fenaux P, Preudhomme C. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders? Haematologica. 1999;84:1075–80.PubMedGoogle Scholar
  67. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–7.PubMedCrossRefGoogle Scholar
  68. Ruggeri M, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111:666–71.PubMedCrossRefGoogle Scholar
  69. Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J Intern Med. 1991;229:493–5.PubMedCrossRefGoogle Scholar
  70. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30:95–108.PubMedCrossRefGoogle Scholar
  71. Smith RE, Chelmowski MK, Szabo EJ. Myelofibrosis: a review of clinical and pathologic features and treatment. Crit Rev Oncol Hematol. 1990;10:305–14.PubMedCrossRefGoogle Scholar
  72. Stoltzfus RJ. Iron-deficiency anemia: reexamining the nature and magnitude of the public health problem. Summary: implications for research and programs. J Nutr. 2001;131:697S–700.PubMedGoogle Scholar
  73. Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood. 1992;80:2052–9.PubMedGoogle Scholar
  74. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.Google Scholar
  75. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108:2173–81.PubMedCrossRefGoogle Scholar
  76. Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010;34:969–73.PubMedCentralPubMedCrossRefGoogle Scholar
  77. Tabarroki A, Tiu RV. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs. 2012;21:1141–54.PubMedCrossRefGoogle Scholar
  78. Tefferi A. How I treat myelofibrosis. Blood. 2011;117:3494–504.PubMedCrossRefGoogle Scholar
  79. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:285–93.PubMedGoogle Scholar
  80. Tinegate H, Gaunt L, Hamilton PJ. The 5q-syndrome: an underdiagnosed form of macrocytic anaemia. Br J Haematol. 1983;54:103–10.PubMedCrossRefGoogle Scholar
  81. Tiu RV, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117:4552–60.PubMedCrossRefGoogle Scholar
  82. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease. Thromb Res. 2007;120:805–10.PubMedCrossRefGoogle Scholar
  83. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251:437–8.PubMedCrossRefGoogle Scholar
  84. Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program 2007;363–70.Google Scholar
  85. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.PubMedCrossRefGoogle Scholar
  86. Visconte V, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012a;26:542–5.PubMedCrossRefGoogle Scholar
  87. Visconte V, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012b;120:3173–86.PubMedCrossRefGoogle Scholar
  88. Vlacha V, Feketea G. Thrombocytosis in pediatric patients is associated with severe lower respiratory tract inflammation. Arch Med Res. 2006;37:755–9.PubMedCrossRefGoogle Scholar
  89. Wickenhauser C, Lorenzen J, Thiele J, Hillienhof A, Jungheim K, Schmitz B, Hansmann ML, Fischer R. Secretion of cytokines (interleukins-1 alpha, -3, and -6 and granulocyte-macrophage colony-stimulating factor) by normal human bone marrow megakaryocytes. Blood. 1995;85:685–91.PubMedGoogle Scholar
  90. Williams E. Thrombocytosis associated with low-molecular-weight heparin. Ann Intern Med. 1997;126:742–3.PubMedCrossRefGoogle Scholar
  91. Zhang Y, Rowley JD. Chronic myeloid leukemia: current perspectives. Clin Lab Med. 2011;31:687–98. doi: 10.1016/j.cll.2011.08.012.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Nemours Center for Childhood Cancer ResearchA.I. duPont Hospital for ChildrenWilmingtonUSA
  2. 2.Taussig Cancer InstituteCleveland ClinicClevelandUSA

Personalised recommendations